# EDGAR Filing Document

**Accession Number:** 0001745114
**File Stem:** 0001745114-25-000037
**Filing Date:** 2025-10
**Character Count:** 43556
**Document Hash:** 0111388597dcd12808105393a7b55de3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001745114-25-000037.hdr.sgml**: 20251030

**ACCESSION NUMBER**: 0001745114-25-000037

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251030

**DATE AS OF CHANGE**: 20251030

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MOLECULAR PARTNERS AG
- **CENTRAL INDEX KEY:** 0001745114
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40488
- **FILM NUMBER:** 251435326

**BUSINESS ADDRESS:**
- **STREET 1:** WAGISTRASSE 14
- **CITY:** Schlieren-Zurich
- **STATE:** V8
- **ZIP:** 8952
- **BUSINESS PHONE:** 41 44 755 77 00

**MAIL ADDRESS:**
- **STREET 1:** WAGISTRASSE 14
- **CITY:** Schlieren-Zurich
- **STATE:** V8
- **ZIP:** 8952

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of October 2025**

**Commission File Number: 001-40488**

**MOLECULAR PARTNERS AG**

**(Exact name of registrant as specified in its charter)**

**Wagistrasse 14**

**8952 Zürich-Schlieren**

**Switzerland**

**Telephone: +41 447557700**

**(Address of registrant's principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F&nbsp;&nbsp;&nbsp;&nbsp;☐ Form 40-F

------

**EXPLANATORY NOTE**

Molecular Partners AG (the "Registrant") is filing this Form 6-K to furnish (i) a press release the Registrant issued on <br>October 30, 2025, (ii) condensed consolidated interim financial statements (unaudited) as of, and for the three and nine months ended September 30, 2025 (including accompanying notes thereto), which are furnished herewith as Exhibit 99.1, and 99.2, respectively.

Exhibits 99.1 and 99.2 to this Report on Form 6-K, excluding any quotes of management, website addresses or hyperlinks included therein, shall be deemed to be incorporated by reference into the Registrant's Registration Statements on Form F-3 (File No. 333-265960) and Forms S-8 (File No. 333-272974 and File No. 333-280491) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

---

| | |
|:---|:---|
| **<u>Exhibit</u>** | |
| 99.1 | <u>[Press release dated October 30, 2025](prq32025forsecfiling.htm)</u> |
| 99.2 | <u>[C](#ia8eb9b68834a4e59aea317068dfb1fc2_68)[ondensed consolidated interim financial statements](#ia8eb9b68834a4e59aea317068dfb1fc2_68)[for the three and nine months ended September 30, 2025,](#ia8eb9b68834a4e59aea317068dfb1fc2_68)[and accompanying notes (unaudited)](#ia8eb9b68834a4e59aea317068dfb1fc2_68)</u> |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **<u>Molecular Partners AG</u>** | **<u>Molecular Partners AG</u>** |
| | (Registrant) | (Registrant) |
| Date: October 30, 2025 | <u>/s/ PATRICK AMSTUTZ</u> | <u>/s/ PATRICK AMSTUTZ</u> |
| | Name: | Patrick Amstutz |
| | Title: | Chief Executive Officer |

---

------

Condensed consolidated interim financial statements (unaudited)

---

| | | | |
|:---|:---|:---|:---|
| Condensed consolidated interim statement of financial position as of |  | September 30, 2025 | December 31, 2024 |
| in CHF thousands | Note |  |  |
| Assets |  |  |  |
| Property, plant and equipment |  | 3185 | 4198 |
| Intangible assets |  | 5 | 49 |
| Total non-current assets |  | 3190 | 4247 |
| Short-term time deposits |  | 22162 | 85565 |
| Other current assets |  | 2335 | 2525 |
| Trade and other receivables |  | 2103 | 2317 |
| Cash and cash equivalents |  | 82359 | 63874 |
| Total current assets |  | 108960 | 154281 |
| Total assets |  | 112150 | 158528 |
| Shareholders' equity and liabilities |  |  |  |
| Share capital | 5.2 | 4037 | 4036 |
| Additional paid-in capital |  | 388209 | 384875 |
| Treasury share reserve | 5.2 | (1129) | (981) |
| Cumulative losses |  | (295588) | (246293) |
| Total shareholders' equity |  | 95529 | 141636 |
| Trade and other payables |  | 160 |  |
| Lease liability |  | 308 | 1227 |
| Employee benefits | 5.8 | 4410 | 4879 |
| Total non-current liabilities |  | 4879 | 6106 |
| Trade and other payables |  | 2123 | 1859 |
| Accrued expenses |  | 8395 | 7709 |
| Lease liability |  | 1224 | 1217 |
| Total current liabilities |  | 11742 | 10786 |
| Total liabilities |  | 16621 | 16892 |
| Total shareholders' equity and liabilities |  | 112150 | 158528 |

---

*See accompanying notes, which form an integral part of these unaudited condensed consolidated interim financial statements.* 

------

---

| | | | |
|:---|:---|:---|:---|
| Condensed consolidated interim statement of profit or loss and other comprehensive result for the 9 months ended September 30, |  | 2025 | 2024 |
| in CHF thousands | Note |  |  |
| Revenues and other income |  |  |  |
| Revenues from research and development collaborations | 5.1 |  | 4970 |
| Total revenues and other income |  |  | 4970 |
| Operating expenses |  |  |  |
| Research and development expenses |  | (30954) | (38055) |
| Selling, general and administrative expenses |  | (11815) | (13338) |
| Restructuring expenses | 5.10 | (2733) |  |
| Total operating expenses |  | (45502) | (51393) |
| Operating result |  | (45502) | (46423) |
| Financial income | 5.5 | 1288 | 3641 |
| Financial expenses | 5.5 | (4790) | (29) |
| Net finance result |  | (3502) | 3612 |
| Result before income taxes |  | (49004) | (42811) |
| Income taxes | 5.6 | 2 |  |
| Net result, attributable to shareholders |  | (49002) | (42811) |
| Other comprehensive result |  |  |  |
| Items that will not be reclassified to profit or loss |  |  |  |
| Remeasurement of net pension liabilities, net of tax |  | (301) | 2088 |
| Items that are or may be reclassified subsequently to profit or loss |  |  |  |
| Exchange differences on translating foreign operations |  | 9 | (10) |
| Other comprehensive result, net of tax | 5.8 | (292) | 2078 |
| Total comprehensive result, attributable to shareholders |  | (49295) | (40733) |
| Basic and diluted net result per share (in CHF) | 5.7 | (1.32) | (1.29) |

---

&nbsp;&nbsp;&nbsp;&nbsp;

*See accompanying notes, which form an integral part of these unaudited condensed consolidated interim financial statements.*

------

---

| | | | |
|:---|:---|:---|:---|
| Condensed consolidated interim statement of profit or loss and other comprehensive result for the 3 months ended September 30, |  | 2025 | 2024 |
| in CHF thousands | Note |  |  |
| Revenues and other income |  |  |  |
| Revenues from research and development collaborations | 5.1 |  | 681 |
| Total revenues and other income |  |  | 681 |
| Operating expenses |  |  |  |
| Research and development expenses |  | (8328) | (10864) |
| Selling, general and administrative expenses |  | (3602) | (4406) |
| Restructuring expenses | 5.10 | (116) |  |
| Total operating expenses |  | (12045) | (15270) |
| Operating result |  | (12045) | (14589) |
| Financial income | 5.5 | 366 | 718 |
| Financial expenses | 5.5 | (157) | (2533) |
| Net finance result |  | 209 | (1815) |
| Result before income taxes |  | (11836) | (16404) |
| Income taxes | 5.6 |  |  |
| Net result, attributable to shareholders |  | (11836) | (16404) |
| Other comprehensive result |  |  |  |
| Items that will not be reclassified to profit or loss |  |  |  |
| Remeasurement of net pension liabilities, net of tax |  | (372) | (1444) |
| Items that are or may be reclassified subsequently to profit or loss |  |  |  |
| Exchange differences on translating foreign operations |  | 3 | (6) |
| Other comprehensive result, net of tax | 5.8 | (370) | (1450) |
| Total comprehensive result, attributable to shareholders |  | (12206) | (17854) |
| Basic and diluted net result per share (in CHF) | 5.7 | (0.33) | (0.49) |

---

*See accompanying notes, which form an integral part of these unaudited condensed consolidated interim financial statements.* 

------

---

| | | |
|:---|:---|:---|
| Condensed consolidated interim cash flow statement for the 9 months ended September 30, | 2025 | 2024 |
| in CHF thousands |  |  |
| Net result attributable to shareholders | (49002) | (42811) |
| &nbsp;&nbsp;&nbsp;Adjustments for: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 1632 | 1799 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation costs | 3446 | 3045 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Social security and tax paid on behalf of employees on shares vested under the PSU and RSU program | (322) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in employee benefits | (770) | 491 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax | (2) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial income | (1288) | (3641) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial expenses | 4790 | 29 |
| Changes in working capital: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in other current assets | 131 | 435 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in trade and other receivables | 215 | (1348) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in trade and other payables | 425 | 1053 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in contract liability |  | (4333) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in accrued expenses | 687 | (709) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exchange gain/(loss) on working capital positions | (24) | (34) |
| Interest paid | (12) | (19) |
| Other financial expense | (11) | (10) |
| Net cash used in operating activities | (40106) | (46053) |
| Proceeds from investments in short term time deposits | 115591 | 222492 |
| Investments in short term time deposits | (55765) | (180246) |
| Acquisition of property, plant and equipment | (575) | (569) |
| Acquisition of intangible assets |  | (17) |
| Interest received | 1346 | 3320 |
| Net cash from investing activities | 60597 | 44980 |
| Proceeds from issuance of shares under LTI plans | 1 |  |
| Proceeds from vesting under the LTI plans, net of transaction costs | 62 | 37 |
| Payment of lease liabilities | (912) | (905) |
| Net cash used in financing activities | (849) | (868) |
| Exchange gain (loss) on cash positions | (1159) | 384 |
| Net decrease in cash and cash equivalents | 18485 | (1557) |
| Cash and cash equivalents at January 1 | 63874 | 67309 |
| Cash and cash equivalents at September 30, | 82359 | 65752 |

---

*See accompanying notes, which form an integral part of these unaudited condensed consolidated interim financial statements.* 

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Condensed consolidated interim statement of changes in equity |  |  |  |  |  |
| in CHF thousands | Share capital | Additional paid-in capital | Treasury share reserve | Cumulative losses | Total shareholders' equity |
| At January 1, 2024 | 3635 | 365530 | (981) | (191755) | 176429 |
| Net result |  |  |  | (42811) | (42811) |
| Remeasurement of net pension liabilities |  |  |  | 2088 | 2088 |
| Exchange differences on translating foreign operations |  |  |  | (10) | (10) |
| Total comprehensive income |  |  |  | (40733) | (40733) |
| Share-based compensation costs <sup>(1)</sup> |  | 3045 |  |  | 3045 |
| Exercise of stock options, net of transaction costs | 34 | 3 |  |  | 37 |
| At September 30, 2024 | 3669 | 368578 | (981) | (232488) | 138778 |
| At January 1, 2025 | 4036 | 384875 | (981) | (246293) | 141636 |
| Net result |  |  |  | (49002) | (49002) |
| Remeasurement of net pension liabilities |  |  |  | (301) | (301) |
| Exchange differences on translating foreign operations |  |  |  | 9 | 9 |
| Total comprehensive income |  |  |  | (49294) | (49294) |
| Share-based compensation costs <sup>(1)</sup> |  | 3446 |  |  | 3446 |
| Issuance of new shares under LTI plans, net of transaction costs | 1 |  |  |  | 1 |
| Exercise of LTI plans, net of transaction costs |  | (112) | 173 |  | 62 |
| Treasury shares withheld to cover social security and tax |  |  | (322) |  | (322) |
| At September 30, 2025 | 4037 | 388209 | (1129) | (295588) | 95529 |

---

<sup>(1)</sup> See note 5.4

*See accompanying notes, which form an integral part of these unaudited condensed consolidated interim financial statements.*

------

Explanatory notes to the condensed consolidated interim financial statements

1.&nbsp;&nbsp;&nbsp;&nbsp;General Information

Molecular Partners AG ("Company") and its subsidiary (collectively "Molecular Partners" or "Group") is a clinical-stage biopharmaceutical company pioneering designed ankyrin repeat proteins (DARPin) candidates to treat serious diseases, with a current focus on oncology and virology. The Company was founded on November 22, 2004, and is domiciled at Wagistrasse 14, 8952 Schlieren, Canton of Zurich, Switzerland. It is subject to the provisions of the articles of association and to article 620 et seq. of the Swiss Code of Obligations, which describe the legal requirements for limited companies ("Aktiengesellschaften").

Molecular Partners Inc. is a wholly owned subsidiary of Molecular Partners AG. Molecular Partners Inc. was incorporated in the United States in the State of Delaware on October 8, 2018. Molecular Partners Inc. is based in Cambridge, Massachusetts.

The unaudited condensed consolidated interim financial statements for the three and nine months ended September 30, 2025 were approved for issuance by the Audit and Finance Committee on October 27, 2025.

The Company's shares have been listed on the SIX Swiss Exchange (Ticker: MOLN) since November 5, 2014 and on the Nasdaq Global Select Market (Ticker: MOLN) since June 16, 2021.

2.&nbsp;&nbsp;&nbsp;&nbsp;Basis of Preparation

These unaudited condensed consolidated interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting and should be read in conjunction with the Group's last annual consolidated financial statements as at and for the year ended December 31, 2024. They do not include all the information required for a complete set of consolidated financial statements prepared in accordance with IFRS Accounting Standards as issued by the IASB. However, selected explanatory notes are included to explain events and transactions that are significant to gain an understanding of the changes in the Group's financial position and performance since the last annual consolidated financial statements as at and for the year ended December 31, 2024.

The accounting policies set forth in the notes to those annual consolidated financial statements have been consistently applied to all periods presented, except as per below.

The condensed consolidated interim financial statements are presented in thousands of Swiss Francs (TCHF), unless stated otherwise.

The business is not subject to any seasonality. Revenues largely depend on the underlying alliance contracts and the achievement of agreed milestones, while expenses are largely affected by the phase of the respective projects, particularly with regard to external research and development expenditures.

Due to rounding, the numbers presented in the financial statements might not precisely equal the accompanying notes.

3.&nbsp;&nbsp;&nbsp;&nbsp;New or Revised IFRS Standards and Interpretations

New or revised standards have been published on or after January 1, 2025 that are not yet effective and that have not been early adopted. Possible impacts have not yet been assessed.

------

4.&nbsp;&nbsp;&nbsp;&nbsp;Accounting estimates and judgments

The condensed consolidated interim financial statements have been prepared under the historical cost convention. In preparing these condensed consolidated interim financial statements, management made judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expenses. Actual results may differ from these estimates.

5.&nbsp;&nbsp;&nbsp;&nbsp;Other explanatory notes

5.1&nbsp;&nbsp;&nbsp;&nbsp;Revenue and other group-wide disclosures

On January 5, 2024 , the Group announced it entered into a co-development agreement with Orano Med to co-develop <sup>212</sup>Pb-based Radio Darpin Therapies (RDT). Under the terms of the co-development agreement, Molecular Partner's RDT target DLL3 (delta-like ligand 3) is included in the collaboration with Orano Med. Both companies agree to share the cost of preclinical and clinical development with additional commitments to supply their respective materials.

The cost sharing in the third quarter of 2025 resulted in a reimbursement of expenses from Orano Med to Molecular Partners of TCHF 633 (the third quarter of 2024 recorded a reimbursement by Molecular Partners to Orano Med of TCHF 425). For the nine months period ended September 30, 2025 the Group recorded a reimbursement of expenses from Orano Med to Molecular Partners of TCHF 2,030 (nine months ended September 30, 2024: a reimbursement by Molecular Partners to Orano Med of TCHF 854), all reported under research and development expenses.

On December 14, 2021, the Group entered into a License and Collaboration Agreement with Novartis to develop DARPin-conjugated radioligand therapeutic candidates for oncology. The collaboration activities ended in the third quarter of 2024. During the three and nine months ended September 30, 2025, the Group recognized no revenue in relation to this agreement (three months ended September 30, 2024: the Group recognized revenue of TCHF 681 and for the nine months ended September 30, 2024: the Group recognized revenue of TCHF 4,970).

Revenues in the table below are attributable to individual countries and are based on the location of the Group's collaboration partners.

---

| | | |
|:---|:---|:---|
| Revenues by country |  |  |
| in TCHF, for the nine months ended September 30 | 2025 | 2024 |
| Switzerland |  | 4970 |
| Total revenues |  | 4970 |

---

---

| | | |
|:---|:---|:---|
| Analysis of revenue by major alliance partner |  |  |
| in TCHF, for the nine months ended September 30 | 2025 | 2024 |
| Novartis AG, Switzerland |  | 4970 |
| Total revenues |  | 4970 |

---

---

| | | |
|:---|:---|:---|
| Revenues by country |  |  |
| in TCHF, for the three months ended September 30 | 2025 | 2024 |
| Switzerland |  | 681 |
| Total revenues |  | 681 |

---

------

---

| | | |
|:---|:---|:---|
| Analysis of revenue by major alliance partner |  |  |
| in TCHF, for the three months ended September 30 | 2025 | 2024 |
| Novartis AG, Switzerland |  | 681 |
| Total revenues |  | 681 |

---

5.2&nbsp;&nbsp;&nbsp;&nbsp;Issuances of equity securities

As of September 30, 2025, as a result of the vesting of Performance Share Units ("PSUs") the outstanding issued share capital of the Company increased to CHF 4,037,464 divided into 40,374,641 fully paid registered shares, inclusive of 2,975,489 treasury shares (December 31, 2024: CHF 4,036,310 divided into 40,363,095 shares, of which 3,500,000 were treasury shares).

---

| | | | |
|:---|:---|:---|:---|
| In CHF thousands | Number of Treasury shares | Average price in CHF | Total TCHF value |
| As of January 1, 2025 | 3500000 | 0.28 | 981 |
| Shares vested under the PSU program | (585783) | 0.28 | (164) |
| Shares withheld to cover social security and tax liabilities | 87447 | 3.42 | 299 |
| Shares vested under the RSU program | (33015) | 0.28 | (9) |
| Shares withheld to cover social security and tax liabilities | 6840 | 3.28 | 22 |
| Shares as of September 30, 2025 | 2975489 | 0.38 | 1129 |

---

<br>Treasury shares are measured at a FIFO principle.

The 94,287 shares were withheld from vested awards to cover employees' and Board of Directors income tax and social security contributions.

5.3&nbsp;&nbsp;&nbsp;&nbsp;Dividends

The Group has paid no dividends since its inception and does not anticipate paying dividends in the foreseeable future.

5.4&nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation

As of September 30, 2025, a total of 2,852,439 PSUs and 504,543 Restricted Stock Units ("RSUs") were outstanding, of which none were vested (as of December 31, 2024 a total of 2,247,267 PSUs and 345,798 RSUs were outstanding). The changes in the number of share-based awards (PSUs and RSUs) outstanding during the nine month period ended September 30, 2025, is as follows:

------

---

| | |
|:---|:---|
| PSU/ RSU movements<sup>3</sup> | PSU / RSU (numbers) |
| **Balance outstanding at January 1, 2025** | **2593065** |
| Granted | 1770707 |
| (Performance adjustment)<sup>1</sup> | (309959) |
| (Forfeited)<sup>2</sup> | (66487) |
| (Expired) |  |
| (Exercised grants), vested PSU / RSU | (630344) |
| **Balance outstanding at September 30, 2025** | **3356982** |

---

<sup>1</sup>Performance adjustments indicate additional grants or forfeitures due to non-market performance conditions (under) over-achieved

<sup>2</sup>Forfeited due to service conditions not fulfilled

<sup>3</sup> All outstanding PSU / RSU have an exercise price of CHF 0.10.

The share-based compensation costs recognized during the nine months ended September 30, 2025, amounted to TCHF 3,446 (TCHF 3,045 for the nine months ended September 30, 2024). For the three months ended September 30, 2025 the share-based compensation costs amounted to TCHF 1,076 (TCHF 1,062 for the three months ended September 30, 2024).

5.5&nbsp;&nbsp;&nbsp;&nbsp;Financial income and expense

Financial income

---

| | | |
|:---|:---|:---|
| in CHF thousands, for the nine months ended September 30 | 2025 | 2024 |
| Interest income on financial assets held at amortized cost | 1288 | 2733 |
| Net foreign exchange gain |  | 908 |
| Total | 1288 | 3641 |

---

---

| | | |
|:---|:---|:---|
| in CHF thousands, for the three months ended September 30 | 2025 | 2024 |
| Interest income on financial assets held at amortized cost | 366 | 718 |
| Total | 366 | 718 |

---

Financial expense

---

| | | |
|:---|:---|:---|
| in CHF thousands, for the nine months ended September 30 | 2025 | 2024 |
| Net foreign exchange loss | (4767) |  |
| Interest expense on leases | (12) | (19) |
| Other financial expenses | (11) | (10) |
| Total | (4790) | (29) |

---

---

| | | |
|:---|:---|:---|
| in CHF thousands, for the three months ended September 30 | 2025 | 2024 |
| Net foreign exchange loss | (151) | (2524) |
| Interest expense on leases | (3) | (6) |
| Other financial expenses | (4) | (3) |
| Total | (158) | (2533) |

---

Exchange results primarily represent unrealized foreign exchange results on the cash and short-term time deposit balances held in USD.

------

5.6&nbsp;&nbsp;&nbsp;&nbsp;Income taxes

The Group has in recent years reported operating losses, with the exception of the year ended December 31, 2022, that resulted in a tax loss carry-forward in Switzerland of TCHF 195,126 as of December 31, 2024. No deferred tax assets have been recognized for these tax loss carry forwards, because it is not probable that such loss carry forwards can be utilized in the foreseeable future. In addition, no deferred tax positions were recognized on other deductible temporary differences (e.g. pension liabilities under IAS 19) due to the significant tax loss carry forwards.

5.7&nbsp;&nbsp;&nbsp;&nbsp;Earnings per share

---

| | | |
|:---|:---|:---|
| for the nine months ended September 30 | 2025 | 2024 |
| Weighted average number of shares used in computing basic and diluted earnings per share | 37,223,971 | 33,082,140 |

---

---

| | | |
|:---|:---|:---|
| for the three months ended September 30 | 2025 | 2024 |
| Weighted average number of shares used in computing basic and diluted earnings per share | 37,399,154 | 33,194,037 |

---

5.8&nbsp;&nbsp;&nbsp;&nbsp;Other Comprehensive result

In order to recognize remeasurements of the net defined benefit obligation in the period in which they arise, the Group utilizes its independent actuaries to update the calculation of the defined benefit obligation and plan assets at each reporting date. The primary component of the remeasurement as of and for the nine month period ended September 30, 2025, relates to the restructuring event. See note 5.10 for additional information.

5.9&nbsp;&nbsp;&nbsp;&nbsp;Related parties

The Group did not enter into any related party transactions in the interim periods presented.

5.10&nbsp;&nbsp;&nbsp;&nbsp;Restructuring expense

On June 10, 2025, Molecular Partners announced a planned operational efficiency initiative ("restructuring 2025"), which included a reduction in headcount within R&D. As a result 34 positions - primarily in R&D, but also in supporting functions - were impacted.

For the nine months ended September 30, 2025, the Group recognized TCHF 2,733 as an expense, of which TCHF 1,741 was provided for as at September 30, 2025. The restructuring charges primarily consist of personnel related cost and the majority is expected to lead to cash outflow during the second half of 2025 .

5.11&nbsp;&nbsp;&nbsp;&nbsp;Events after the balance sheet date

No events occurred between the balance sheet date and the date on which these condensed consolidated interim financial statements were approved for issuance by the Audit and Finance Committee that would require adjustment to these condensed consolidated interim financial statements or disclosure under this section.

## Exhibit 99.1

![image_0.jpg](image_0.jpg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *IND application filed for MP0712, the Company's lead Radio-DARPin candidate targeting DLL3 and co-developed with Orano Med, with Phase 1 initiation expected before year end 2025* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *First patient images from MP0712 compassionate care program to be presented at TRP in November; additional programs planned for 2026, including MP0726 targeting mesothelin.* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Updated data from Phase 1/2a trial of MP0533, a multispecific T cell engager for AML, to be presented at ASH in December* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Protocol approved for Phase 2 investigator-initiated trial of FAP x CD40 agonist MP0317*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Strong financial position with cash runway until 2028*

**Zurich-Schlieren, Switzerland and Concord, Mass., October 30, 2025** – **Ad hoc announcement pursuant to Art. 53 LR** Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced corporate highlights and unaudited financial results for the third quarter of 2025.

"We are excited to present initial clinical imaging data this November on MP0712, the 1<sup>st</sup> Radio-DARPin targeting DLL3, from compassionate care use in South Africa. The IND application for MP0712 has been filed and we see the alpha-targeting approaches for DLL3 in lung cancer as a valuable new modality for patients. Building on that progress, we are establishing a pipeline of additional Radio-DARPins with our partner Orano Med for selected targets, including mesothelin for ovarian cancer," said **Patrick Amstutz, Ph.D., CEO of Molecular Partners**. "MP0533 is the first-ever tetraspecific T-cell engager to demonstrate safety and efficacy in AML. We will report additional data on optimized dosing and a deeper understanding on the ideal patient profile for MP0533. This understanding is important to plan next steps and is supportive of positioning of our drug in the treatment landscape."

**Research & Development Highlights**

**MP0712 (**<sup>212</sup>**Pb x DLL3), Radio-DARPin Pipeline and Collaboration with Orano Med**

The Phase 1 Investigational New Drug (IND) application for MP0712, a <sup>212</sup>Pb-based Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3), co-developed with Orano Med for the treatment of small cell lung cancer (SCLC) and other DLL3-expressing neuroendocrine cancers, has been filed. Dialogue with the FDA is

&nbsp;&nbsp;&nbsp;&nbsp;

------

ongoing and, pending regulatory clearance, the Phase 1 trial is expected to initiate before the end of 2025.

Molecular Partners presented preclinical data in April at the American Association for Cancer Research (AACR) Annual Meeting 2025, showing high tumor uptake, promising efficacy and a favorable safety profile for MP0712 in mouse models matching clinically-relevant DLL3 expression levels.

In H1 2025, Molecular Partners accepted a request from the Nuclear Medicine Research Infrastructure (NuMeRI) in South Africa to provide MP0712 for imaging use under the legal framework in South Africa for compassionate care (also referred to as Section 21 of the Medicines and Related Substances Act). This approach enables the generation of initial images applying MP0712 labeled with <sup>203</sup>Pb in patients with SCLC and other DLL3-expressing neuroendocrine cancers. As per courtesy of NuMeRI, the Company will present first images from the MP0712 compassionate care program at the Targeted Radiopharmaceuticals (TRP) Summit EU in November. The NuMeRI team, lead by Dr. Mike Sathekge, plans to report the full imaging and dosimetry data of MP0712 at the Theranostics World Conference (TWC) in January 2026.

<sup>203</sup>Pb and <sup>212</sup>Pb are an element-equivalent pair of lead (Pb) isotopes, with <sup>203</sup>Pb primarily used for imaging and <sup>212</sup>Pb for therapeutic applications (targeted alpha therapy, TAT). As a "matched pair", pre-treatment imaging with <sup>203</sup>Pb provides a prediction of treatment behavior with <sup>212</sup>Pb.

In January 2025, Molecular Partners and Orano Med expanded their agreement to co-develop up to ten radiotherapy programs. In addition to its world class expertise and capabilities in the development of TAT with <sup>212</sup>Pb, Orano Med will ensure the production of the <sup>212</sup>Pb-based Radio-DARPins for clinical trials and commercialization. Orano Med possesses virtually unlimited source material for <sup>212</sup>Pb production and has established robust and independent supply and manufacturing capabilities required for the seamless delivery of TAT to clinical sites internationally.

The second RDT program slated for clinical development is MP0726, targeting mesothelin (MSLN), a tumor target overexpressed across several cancers with high unmet need, such as ovarian cancer. Molecular Partners has developed Radio-DARPins able to selectively bind to membrane-bound MSLN without being impacted by shed MSLN, which has hampered the development of other MSLN-targeted therapeutics. The Company presented preclinical data on MP0726 at the 2025 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) in June. The Company is planning to progress several programs in 2026, including MP0726.

**MP0533 (Multispecific T Cell Engager; CD33 x CD123 x CD70 x CD3)**

MP0533 is currently being evaluated in a Phase 1/2a clinical trial for relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)/AML (NCT05673057). Molecular Partners presented updated data from the study at the 30th Annual European Hematology Association (EHA) Congress in June, with promising antitumor activity observed in cohort 8. Three of 8 (>30%) evaluable patients in this cohort achieved a clinical response after the first cycle, and two patients maintained their responses for over three months, including one patient still on treatment today (>12 months response duration). Cohort 8 benefited from a higher starting dose and a faster step-up dosing schedule, leading to improved exposure within the

------

predicted therapeutic range and notable blast reduction in most patients, with an acceptable safety profile after dose adjustment.

Encouraged by these results, Molecular Partners amended the dosing scheme for cohorts 9 and 10 by further accelerating the step-up dosing, increasing the dosing frequency and introducing anti-CD20 premedication to achieve higher cumulative exposure as well as enhanced depth and duration of responses. Cohort 9 is exploring a lower target dose than cohort 8 to assess the safety of up to daily dosing in the first 14 days of treatment. Data from cohort 9 will be presented at the American Society of Hematology (ASH) Annual Meeting in December 2025. Cohort 10, which aims at reaching the same target dose as cohort 8 while exposing patients to more drug over time, is now enrolling and dosing patients.

MP0533 continues to show broad activity in a mutation-agnostic manner, with initial blast reductions in a majority of patients treated, and an acceptable safety profile. The data continue to indicate that the patients more likely to see durable responses will be those who initiate therapy with a lower level of blasts at baseline. Molecular Partners plans to explore MP0533 in combination settings, both in patients with relapsed/refractory disease as well as in front-line setting, should favorable antitumor activity continue to be observed. Several consortia have approached Molecular Partners expressing interest in conducting such studies. The Company is engaging with key opinion leaders and regulators to discuss next steps.

**MP0317 (Tumor-Localized Agonist; FAP x CD40)**

Molecular Partners is supporting an investigator-initiated trial of MP0317, for which a study protocol has been approved (NCT07036380). This proof-of-concept randomized Phase 2 study, to be conducted by an expert network in France, is designed for the treatment of patients with advanced cholangiocarcinoma in combination with anti-PD-L1 therapy (durvalumab) and gemcitabine-cisplatin-based chemotherapy. The main objective of the study is to assess the 12-month progression free survival (PFS) in the experimental arm (N = 50 patients).

MP0317 is designed to activate immune cells specifically within the tumor microenvironment by anchoring to fibroblast activation protein (FAP), which is expressed in high amounts in the stroma of various solid tumors. The Company believes this tumor-localized approach has the potential to deliver greater efficacy with fewer side effects compared to systemic CD40-targeting therapies. Molecular Partners presented comprehensive biomarker analyses from the completed Phase 1 dose escalation trial of the localized CD40 agonist MP0317 in solid tumors at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November 2024.

**Switch-DARPins (Next-Generation Immune Cell Engagers)**

By employing a multi-specific Switch-DARPin, Molecular Partners aims to increase the safety and potency of T cell engagers (TCEs). Preclinical proof-of-concept for a novel CD3 Switch-DARPin TCE with CD2 costimulation was presented at AACR in April 2025. The data show the feasibility of conditional T cell activation with potent co-stimulation in solid tumors, but not in healthy tissues. In addition, data showed that the CD3 Switch-DARPin activates T cells specifically in the presence of cells co-expressing the tumor targets MSLN and EpCAM, thereby increasing tumor specificity. The Company will present an update on the CD3 Switch-DARPin program at SITC in November 2025.

------

**Corporate Governance Highlights**

Molecular Partners appointed Martin Steegmaier, Ph.D., as Chief Scientific Officer (CSO) and member of its Executive Committee, effective October 1, 2025. Martin brings a wealth of experience in oncology drug development, having previously contributed to the advancement of several innovative cancer therapies at major biotech and pharmaceutical companies.

**Financial and Business Outlook**

For the full year 2025, at constant exchange rates, the Company expects total operating expenses of CHF 55 – 60 million of which around CHF 6 million will be non-cash effective costs for share-based payments, IFRS pension accounting and depreciation.

The Company's cash and cash equivalents and short-term time deposits were CHF 105 million as of September 30, 2025 and based on current operating assumptions, will be sufficient to fund its operating expenses and capital expenditure requirements until 2028.

**Financial Calendar**

March 12, 2026 Full year results 20025 <br> April 14, 2026 Annual General Meeting

**About DARPin Therapeutics**

DARPin (Designed Ankyrin Repeat Protein) therapeutics are a new class of custom-built protein drugs based on natural binding proteins that open new dimensions of multi-functionality and multi-target specificity in drug design. The flexible architecture, intrinsic potential for high affinity and specificity, small size and high stability of DARPins offer benefits to drug design over other currently available protein-based therapeutics. DARPin candidates can be radically simple, with a single DARPin unit acting as the delivery vector to a specific target; or multispecific, with the possibility of engaging more than five targets, and combining multiple and conditional functionalities in a unique DARPin drug candidate. The DARPin platform is designed to be a rapid and cost-effective drug discovery engine, producing drug candidates with optimized properties and high production yields. DARPin therapeutics have been clinically validated across several therapeutic areas and developed through to the registrational stage.

**About Molecular Partners AG** 

Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit <u>www.molecularpartners.com</u> and find us on LinkedIn and Twitter / X <u>@MolecularPrtnrs</u>

------

**For further details, please contact:**

Seth Lewis, SVP Investor Relations & Strategy

Concord, Massachusetts, U.S.

seth.lewis@molecularpartners.com

Tel: +1 781 420 2361

Laura Jeanbart, PhD, Head of Portfolio Management & Communications

Zurich-Schlieren, Switzerland

laura.jeanbart@molecularpartners.com

Tel: +41 44 575 19 35

**Cautionary Note Regarding Forward-Looking Statements** 

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners' product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners' collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners' expected business and financial outlook, including anticipated expenses and cash utilization for 2025 and its expectation of its current cash runway. These statements may be identified by words such as "aim", "anticipate", "expect", "guidance", "intend", "outlook", "plan", "potential", "will" and similar expressions, and are based on Molecular Partners' current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners' expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners' reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners' ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners' ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners' product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners' product candidates; the potential that Molecular Partners' product candidates may exhibit serious adverse, undesirable or unacceptable side effects; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners' preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners' plans and development of any new indications for its product candidates; Molecular Partners' commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners' intellectual property position; Molecular Partners' ability to identify and in-license additional product candidates; unanticipated factors in addition to the foregoing that may cause Molecular Partners' actual results to differ from its financial and business projections and guidance; and other risks and uncertainties set forth in Molecular Partners' Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners' website at www.molecularpartners.com. In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future. Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

<br>